Reyvow patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US7423050 ELI LILLY AND CO Pyridinoylpiperidines as 5-HT1F agonists
Feb, 2028

(4 years from now)

US11053214 ELI LILLY AND CO Compositions and methods related to pyridinoylpiperidine 5-HT1F agonists
Dec, 2037

(14 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8748459 ELI LILLY AND CO Pyridinoylpiperidines as 5-HT1F agonists
Mar, 2023

(5 months ago)

Reyvow is owned by Eli Lilly And Co.

Reyvow contains Lasmiditan Succinate.

Reyvow has a total of 3 drug patents out of which 1 drug patent has expired.

Expired drug patents of Reyvow are:

  • US8748459

Reyvow was authorised for market use on 31 January, 2020.

Reyvow is available in tablet;oral dosage forms.

Reyvow can be used as acute treatment of migraine.

Drug patent challenges can be filed against Reyvow from 2024-02-01.

The generics of Reyvow are possible to be released after 05 December, 2037.

Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Jan 31, 2025

Drugs and Companies using LASMIDITAN SUCCINATE ingredient

NCE-1 date: 2024-02-01

Market Authorisation Date: 31 January, 2020

Treatment: Acute treatment of migraine


More Information on Dosage

REYVOW family patents

Family Patents

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic